CEIV 1.0
Project Purpose
In order to increase the recognition of CEIV by the shippers and their acceptance of the checklist and audit methodology, IATA entrusted Pharma.Aero with an evaluation of the program by and in collaboration with the shippers. This evaluation had a dual purpose: to increase the confidence of shippers by giving them detailed knowledge of the criteria used; and to allow them to add elements to the checklist so that it would better meet their requirements. Based on this feedback, IATA would complement and adjust the program.
Project Objective(s)
The project group evaluates to which extent pharmaceutical manufacturers can validate the checklist and the audit methodology, aiming at obtaining an endorsed audit format.
Project Status And Key-takeaways
Project ongoing, following the steps:
-
Work Package 1: Host and exclusive webinar for the members of both organisations (Pharma.Aero and HLA) on June 15, 2021, followed by a survey. The results of the survey and insights gathered amongst the presenters, the attendees and the project group were outlined in a White Paper. This first report examined the competitive positioning of UAV against other transportation modes, the regulatory framework for drone operations and applications of UAV in the Pharma and Humanitarian Air Cargo sector.
-
Work Package 2: Create a 360° interactive video to showcase drone lab technologies, different types of drones and drone operations. This video is now available for Pharma.Aero members only.
-
Work Package 3: Map the journey of the Covid-19 vaccines from the manufacture point in Europe to the arm of the patient in Malawi. Draft a list of recommendations on how to optimize the end-to-end transportation by shortening the supply chain and linking both traditional airfreight and drone worlds. Disseminate a theoretical proof of concept (technical report and white paper). See here the video of the Vaccines transportation from Belgium to Malawi.
PROJECT
SUPPORT AND
COLLABORATION.
- Project lead: Brussels Airport Company
- Project members: Johnson & Johnson, MSD, Pfizer
- Project manager: Geert Verniers, 4Advice (external consultant)